MedTrace Logo

The Impact of Palm Date Intake on Colon Health Biomarkers

NCT02288611 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2014-11-11

No results posted yet for this study

Summary

This aim of this study is to investigate the prebiotic potential of date fruits in healthy human volunteers compared to a control diet. Each arm was 21 days in duration, separated by a 14 days washout period. Faecal samples, and blood samples will be collected from each volunteer and high resolution analytical techniques (HPLC, LC-MS and NMR) will be employed to characterise the whole system metabolic response to ingestion of date fruits compared to the control. Changes in microbial parameters and metabolite profiles will be correlated with changes in biomarkers of chronic disease, including faecal water genotoxicity, cellular reactions, blood lipids and bowel movements.

Conditions

Interventions

DIETARY_SUPPLEMENT

Date fruit - Ajwa variety

Twenty-two healthy human individuals were randomly assigned to consume 7 date fruits (approx. 50g). Each arm was 21 days in duration, separated by a 14 days washout period.

DIETARY_SUPPLEMENT

Maltodextrin/Dextrose

Twenty-two healthy human individuals were randomly assigned to consume Maltodextrin/dextrose , 40.2g. Each arm was 21 days in duration, separated by a 14 days washout period.

Sponsors & Collaborators

  • University of Reading

    lead OTHER

Principal Investigators

  • JEREMY PE SPENCER, PhD · UNIVERSITY OF READING - FOOD AND NUTRITIONAL SCIENCES DEPARTMENT

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-09-30
Completion
2014-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02288611 on ClinicalTrials.gov